Confirmed Chairs and Speakers

SfC = Strategies for Commercialization
Q&O =
Quality and Operations
ESP = Early Stage Professionals
APP = Advanced Practice Professionals
Listing in alphabetical order by last name. Updated as of March 28, 2017. 
Vicki Antonenas, BSc, MSc, Sydney Cellular Therapies Laboratory, Westmead Hospital, Australia
Q&O Track Session 1
Giuseppe Astori, PhD, Advanced Cellular Therapy Laboratory, Hematology Unit, Vicenza Hospital, Italy
Q&O Track Session 4
John Barrett, MD, National Institute of Health, United States
Plenary Session 3, Cancer Immunotherapy Breakout 2
Jacqueline Barry, PhD, Cell and Gene Therapy Catapult, United Kingdom
SfC Track Session 2
Shirley Bartido, PhD, MBA, Cellectis, United States
Q&O Track Session 1
Gerhard Bauer, PhD, University of California Davis, United States
SfC Track Session 4, ISCT PTF Session
Rosemarie Bell, B.App.Sc Micro/Biochem MASM, QIMR Berghofer Medical Research Institute, Australia
Q&O Track Session 6
Valkal Bhatt, PharmD, BCOP, Memorial Sloan Kettering Cancer Center, United States
APP Track Session 1, APP Track Session 3
Karen Bieback, PhD, Institute of Transfusion Medicine and Immunology , Germany
Hot Topic Session 3
Catherine Bollard, MBChB, MD, Children’s National Medical Center and The George Washington University, United States
Plenary Session 1 
Chiara Bonini, MD, San Raffaele Scientific Institute, Italy
Plenary Session 1, T-Cell Immunotherapy Breakout Session 2
Malcolm Brenner, MChB, PhD , Baylor College of Medicine, United States
Plenary Session 3, Cancer Immunotherapy Breakout Session 1
Wilson Bryan, MD, FDA, United States
Regulatory Track Session 1
Jeff Bulte, PhD, Johns Hopkins Institute for Cell Engineering, United States
HESI CT-TRACS Session
Karen Burks, BSc, NHS Blood & Transplant,  United Kingdom
Q&O Track Session 1
Jorge Burns, PhD, University Hospital of Modena and Reggio Emilia, Italy
Q&O Track Session 4
Lizette Caballero, MLS(ASCP)CM, UCSF BMT Laboratory, United States
Q&O Track Session 6
Ian Campbell, Innovate UK, United Kingdom
SfC Track Session 4
Patrick Celis, PhD, European Medicines Agency, United Kingdom
IPRF Session
Theofanis Chatzistamatiou, PhD, Dubai Cord Blood and Research Center, United Arab Emirates
Regulatory Track Session 2
Fungayi Chidothe, MBchB, MSc, Cell & Gene Therapy Catapult, United Kingdom
SfC Track Session 5
Reginald Clayton, PhD, BioReliance, United Kingdom
Q&O Track Session 2
Chris Creasey, PhD, Asymptote Ltd, United Kingdom
SfC Track Session 2
Lynn Csontos, CQA, STEMCELL Technologies Inc., Canada
SfC Track Session 7
Emily Culme-Seymour, PhD, GSK, United Kingdom
ESP Session 1
Farida Djouad, PhD, French Institute of Health and Medical Research, France
Non-Malignant Diseases Immunotherapy Plenary Breakout 1
Massimo Dominici, MD, University of Modena and Reggio Emilia, Italy
Hot Topic Session 2, ISCT Presidential Task Force Session
Ekaterina Doubrovina, MD, PhD, Memorial Sloan-Kettering Cancer Center, United States
Q&O Track Session 1
Dawn Driscoll, MBA, PhD, DCi Biotech, Australia
SfC Track Session 1
Matthew Durdy, MBA, Cell and Gene Therapy Catapult, United Kingdom
SfC Track Session 3
Simon Ellison, MBA, Fisher BioServices UK, United Kingdom
Plenary Session 4, SfC Track Session 2
Suzanne Farid, PhD, University College London, United Kingdom
Industrial Translation Breakout Session
Eric Faulkner, MPH, Evidera, United States
SfC Track Session 1
Jim Faulkner, PhD, Autolus Ltd, United Kingdom
SfC Track Session 5 
Fernando Figueroa, MD, University of Los Andes, Chile
Plenary Session 3, Non-Malignant Diseases Immunotherapy Plenary Breakout Session 1
Tobi Fisher, PA-C, UT MD Anderson Cancer Center, United States
APP Track Session 1,  APP Track Session 3
Miguel Forte, MD, PhD, mC4Tx, Bone Therapeutics, Belgium
SfC Track Session 4, Hot Topic Session 4, Late Breaking Abstracts Session
Thorsten Friedel, PhD, GSK, United Kingdom
ESP Session 1
Jacques Galipeau, MD FRCP(C), University of Wisconsin in Madison, United States
MSC Oral Abstract Presentations Session 1
Alex Ganetsky, PharmD, Hospital of the University of Pennsylvania, United States
APP Track Session 2,  APP Track Session 3
Saar Gill, MD, PhD, University of Pennsylvania, United States
APP Track Session 2, T-Cell Immunotherapy Breakout Session 2
Maria Gilleece, MD, FRCP, FRCPath, Leeds Teaching Hospitals NHS Trust, United Kingdom
APP Track Session 1
Massimiliano Gnecchi, MD, PhD, FESC, University of Pavia & IRCCS Policlinico San Matteo, Italy
Plenary Session 6 
Rosa Gonzalo, MSc, PhD,University Hospital Puerta de Hierro Majadahonda, Spain
Q&O Track Session 4
Kurt Gunter, MD, Cell Medica Inc, United States
Plenary Session 4, Industrial Translation Breakout Session
Patrick Hanley, PhD, Children’s National Medical Center, United States
ESP Session 1
Shelly Heimfeld, PhD, Fred Hutchinson Cancer Research Center, United States
SfC Track Session 4
Brooke Helfer, PhD, Celsense, United States
HESI CT-TRACS  Session
Olav Hellebø, MBA, ReNeuron, United Kingdom
Plenary Session 4
Helen Heslop, MD, DSc (Hon), Baylor College of Medicine, United States
Plenary Session 1, T-Cell Immunotherapy Plenary Breakout Session 1
Edward Hodgkin, MA, PhD, Syncona Limited, United Kingdom
Hot Topic Session 4
Karen  Hodgkin, MSc, Cell Medica Inc, United Kingdom
SfC Track Session 1
Emily Hopewell, PhD, Moffitt Cancer Center, United States
ESP Session 2
Ying Huang, PhD, FDA, United States
IPRF Session
Saskia Ihle, PhD, Lonza Cologne GmbH, Germany
Q&O Track Session 2
Samuel Janes, MBBS, PhD, University College London, United Kingdom
Hot Topic Session 2
Elena Jones, PhD, University of Leeds, United Kingdom
Hot Topic Session 3
Diane Kadidlo, MT(ASCP), SBB, University of Minnesota, United States
Q&O Track Session 2
Ohad Karnieli, MBA, PhD, ATVIO Biotechnology, Israel
SfC Track Session 7
Aisha Khan, ABD, MSc, MBA, University of Miami, United States
Q&O Track Session 4
Sven Kili, MD, GSK, United Kingdom
Plenary Session 4 
Carlos Lee, BSc, Carolinas Healthcare System, United States
Q&O Track Session 6
Ann Leen, PhD, Baylor College of Medicine, United States
T-Cell Immunotherapy Breakout  1
Megan Levings, PhD, University of British Columbia, Canada
Plenary Session 3, Non-Malignant Diseases Immunotherapy Breakout 3
Giovanna Lombardi, PhD, King’s College London, United Kingdom
Plenary Session 3, Non-Malignant Diseases Immunotherapy Plenary Breakout Session 3
Eleuterio Lombardo, PhD, TiGenix SAU, Spain
Industrial Translation Plenary Breakout Session
Geoffrey MacKay, AVROBIO Inc, United States
SfC Track Session 1
Paolo Madeddu, MD, University of Bristol, United Kingdom
Tissue Engineering Breakout 1
John Maher, MD, PhD, King’s College London, United Kingdom
T-Cell Immunotherapy Plenary Breakout Session 3 
Dalia Mahmoud, PhD, Celgene, United States
SfC Track Session 3
Damian Marshall, PhD, Cell and Gene Therapy Catapult, United Kingdom
Hot Topic Session 6
Ivan Martin, PhD, University Hospital Basel, Switzerland
Plenary Session 6
Sandro Matosevic, PhD, Akron Biotech, United States
SfC Track Session 6
Gerry McKiernan, Cell Therapies PTY, Australia
Q&O Track Session 5
Michael Mendicino, PhD, Hybrid Concepts International, United States
ESP Session 2
Stephan Mielke, MD, PhD, University of Wuerzburg, Germany
Plenary Session 3, Cancer Immunotherapy  Breakout Session 3
William Milligan, BSc, Steminent Biotherapeutics Inc., Canada
Hot Topic Session 3, SfC Track Session 3
William Mirsch, MBA, Mill Creek Life Sciences, United States
Hot Topic Session 3
Emma Morris, PhD, University College London, United Kingdom
APP Track Session 2
Brian Newsom, MBA, Thermo Fisher Scientific, United States
SfC Track Session 6
Karen Nichols, Esq., NantKwest, United States
Regulatory Track Session 1, ISCT Presidential Task Force Session
Kyle Norrie, BSc, Health Canada, Canada
Regulatory Track Session 1
Peter Olagunju, MBA, bluebird bio, United States
SfC Track Session 2
Alex Pasteur, PhD, F-Prime, United Kingdom
Hot Topic Session 4
Aimee Payne, MD, PhD, University of Pennsylvania, United States
Plenary Session 3, Non-Malignant Diseases Immunotherapy Breakout 3
Karl Peggs, MD, MRCP, FRCPath, University College London, United Kingdom
T-Cell Immunotherapy Breakout 1
Madhusudan V. Peshwa, PhD, MaxCyte Inc., United States
Hot Topic Session 5
Donald G. Phinney, PhD, The Scripps Research Institute, United States
MSC Oral Abstract Presentations Session 1
Avery Posey, PhD, University of Pennsylvania, United States
ESP Session 1 
Nicole Prokopishyn, PhD , Calgary Laboratory Services, Canada
Q&O Track Session 5
Martin Pule, MB BCh, University College London, United Kingdom
Plenary Session 1, T-Cell Immunotherapy Breakout 3
John Rasko, MBBS, PhD, FRCPA, FRCAP, Royal Prince Alfred Hospital, Australia
Plenary Session 5, ESP Session 2
Lola Reid, PhD, University of North Carolina at Chapel Hill, United States
Plenary Session 6, Tissue Engineering Breakout 2
Stephan Reynier, MSc, Cellectis SA, France
Q&O Track Session 3
Katy Rezvani, MD, PhD, MD Anderson Cancer Center, United States
Plenary Session 3
Rodney Rietze, PhD, Novartis, United States
SfC Track Session 7
Patrick Rivers, BSc, MBA, Aquilo Capital, United States
Hot Topic Session 4, Industrial Translation Plenary Breakout Session
Robyn Rodwell, PhD, Queensland Cord Blood Bank At The Mater, Australia
Q&O Track Session 5
Cliona Rooney, PhD, Baylor College of Medicine, United States
Hot Topic Session 5
Pablo Ross, PhD, UC Davis, United States
Plenary Session 5
Yoji Sato, PhD, NIHS Japan, Japan
HESI CT-TRACS Joint Session
Katharina Schallmoser, MD, Paracelsus Medical University of Salzburg, Austria
Hot Topic Session 3
Khalid Shah, MS, PhD, MGH, Harvard Medical School, United States
Hot Topic Session 1
William Shingleton, PhD, GE Healthcare, United Kingdom
HESI CT-TRACS Joint Session
Nick Stephens, LLB, The RSA Group, United Kingdom
SfC Track Session 5
Olive Sturtevant, MT (ASCP), MHP, Dana Farber Cancer Institute, United States
Q&O Track Session 1
Jacqui Thompson, BSc, NHSBT Birmingham, United Kingdom
Q&O Track Session 6
Adrian Thrasher, MBBS, PhD, University College London, United Kingdom
Plenary Session 5
Annette Trickett, PhD, Prince of Wales Hospital, Australia
Q&O Track Session 5
Douglas Turnbull, MBBS, PhD, Newcastle University, United Kingdom
Plenary Session 5
Marc Turner, MBChB, PhD, MBA, Scottish National Blood Transfusion Service, Scotland
Plenary Session 4
Nobuhiro Umeda, PhD, Astellas Pharma Inc., Japan
HESI CT-TRACS Session
Christopher Vann, BSc, Autolus Ltd, United Kingdom
SfC Track Session 3
Paul Veys, MBBS, FRCP, FRCPath, FRCPCH, Great Ormond Street Hospital for Children, United Kingdom
Q&O Track Session 3
Sowmya Viswanathan, PhD, University Health Network, Canada
Regulatory Track Session 1, Q&O Track Session 2
Dominic Wall, PhD, FFSc(RCPA), Peter MacCallum Cancer Centre, Australia
Regulatory Track Session 2
Ivan Wall, PhD, FRSB, CBiol, AMIChemE, AHEA, University College London, United Kingdom
Hot Topic Session 6
Wen Bo Wang, PhD, Cellular Dynamics International, a Fujifilm company, United States
Hot Topic Session 1
Ben Weil, MRes, EngD, University College London, United Kingdom
Hot Topic Session 1, ESP Session 1
Daniel J. Weiss, MD, PhD, University of Vermont College of Medicine, United States
ISCT CSO Abstract Showcase, ISCT Presidential Task Force Session
Craig Wright, MSc, Royal Prince Alfred Hospital, Australia
Q&O Track Session 1
Jiwen Zhang, PhD, GE Healthcare, United States
SfC Track Session 7

 

ISCT 2017

ISCT 2017